{"name":"Hangzhou Sciwind Biosciences Co., Ltd.","slug":"hangzhou-sciwind-biosciences-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Ecnoglutide High Dosage","genericName":"Ecnoglutide High Dosage","slug":"ecnoglutide-high-dosage","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Ecnoglutide Low Dosage","genericName":"Ecnoglutide Low Dosage","slug":"ecnoglutide-low-dosage","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Ecnoglutide Medium Dosage","genericName":"Ecnoglutide Medium Dosage","slug":"ecnoglutide-medium-dosage","indication":"Type 2 diabetes mellitus","status":"phase_3"}]}],"pipeline":[{"name":"Ecnoglutide High Dosage","genericName":"Ecnoglutide High Dosage","slug":"ecnoglutide-high-dosage","phase":"phase_3","mechanism":"Ecnoglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion and improve glycemic control.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Ecnoglutide Low Dosage","genericName":"Ecnoglutide Low Dosage","slug":"ecnoglutide-low-dosage","phase":"phase_3","mechanism":"Ecnoglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion and improve glycemic control.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Ecnoglutide Medium Dosage","genericName":"Ecnoglutide Medium Dosage","slug":"ecnoglutide-medium-dosage","phase":"phase_3","mechanism":"Ecnoglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion and improve glycemic control.","indications":["Type 2 diabetes mellitus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-02-24","type":"deal","source":"The Manila Times","summary":"Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China - The Manila Times","headline":"Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNdHdQS2h6OS1wMUJjTFU4aHBEdkdSRW9RSTdkUXZhaG9KcnNiOFloRlhOYVItTVE0dHgwZ2dnY2lDSEppYW9NY2swUjRzajdpeWtBSXBHWEt1N3VMWHNaUDZxTHBiYWtmSjFzWDUzbzFNaGZUcDBDRXdPc0hPOUhuSUtzWkc2bnpnbG1oaG44T2J5NjNjbjh3b01YUGhKaGxOUXFweE5XU3hlX3RmRnlnRGRuX016UTZGbGJ0TTBTdw?oc=5","date":"2026-02-23","type":"deal","source":"Reuters","summary":"Pfizer in diabetes drug deal with Sciwind Biosciences - Reuters","headline":"Pfizer in diabetes drug deal with Sciwind Biosciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQR2lKd1FyZTltbTVmcXNOMklnUWNNcXRzeGk3THF6TE90N250aUp1dFRPV1Myb05LMVhINUp5QktFbXBaRFQxc2hiQzJIcmtCNUYteGpscVhBVE5GR1AtUlFKd0VIb0xoX2ZOR2F3LTFrNldSYk1fc3VmNG9RZWwyQURnZHljdGw5U1d2T2liQXc2UVhGNjA3bGZ5cG4tcTdRRVp5QUZGSjlaUkFxWmFGMXZDanRPMnFUT3N3WQ?oc=5","date":"2026-01-30","type":"regulatory","source":"Reuters","summary":"Sciwind Biosciences diabetes drug approved in China - Reuters","headline":"Sciwind Biosciences diabetes drug approved in China","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQR2luT1hpSDlmbmtCSklfQ0YtcjF0NFpqdlkyb3V2VXpNckJjZ3BvNDZLTnlES3U5RUd0RHBZbDFDMGZtdFJKU29zVVljU1ZLXzJwc1FmMkhCaUpiXzUwUV9RU1lzbV83R2k0NE41Q3E2clRyWFdUYnNrS042ajB2NGxxSURxU3JqUDBKcXI3SWUzUGxaTnc?oc=5","date":"2025-10-09","type":"pipeline","source":"thebambooworks.com","summary":"Obesity drug maker Sciwind targets IPO, with heavyweight backers - thebambooworks.com","headline":"Obesity drug maker Sciwind targets IPO, with heavyweight backers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxONzhBVTJSZ2NoRGVkSDdJS1NtRmhCbDZDQUFRQ0RXbmdIeF9QVXNFY3BJUHJ3VXJwei0xVU11VVJXZDVGOEJFbDZqN1JXNmlObEVsVzFIOFQtTHE3bzV2V2I3emtCYS1aQXp5RFk5OE85LUU0Z1JtSzlQMjhfMkhFRU1ya21rNy1CSzdXMnR0M2c4WV9NcFZRTlY1NW1KNTdIMDFKSWZqYklQV0FQLW9IaFhIdk96dEliSE1Ub01jakFJLTBFQ0daOHpsaE4?oc=5","date":"2025-07-25","type":"deal","source":"Reuters","summary":"Exclusive: China's Sciwind is in talks to license weight-loss drug in US, CEO says - Reuters","headline":"Exclusive: China's Sciwind is in talks to license weight-loss drug in US, CEO says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOdVlKMlEyakxpZWJFSTBoaExBXzlsWV9FamxzQTFFMjZ0V3kyNmNEOUloSWxRM3JYOHFDQ29fWTk5Z1NQcjRqb0xtenctMWVWWTE4Mk5xa1NTTzlTRm5NMEhKMFBxOTNaU3NTa0FaR3ExbGZSTUVISm9tdjNialc4XzBkYXZDbG53ZU1QcnJlLWxmN3phcmtjZVUtRkZHREg0MTVOV01kcDZtOTJUNlZNbA?oc=5","date":"2025-06-27","type":"pipeline","source":"Bloomberg.com","summary":"Innovent Wins China Nod For Obesity Drug Rivaling Novo, Lilly - Bloomberg.com","headline":"Innovent Wins China Nod For Obesity Drug Rivaling Novo, Lilly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPc3RLWFNPaEhPUHFYakxTWmVVSzFLM1VMRzNoVGdmRzlhTDZzYk9TVUVaUFVPd2YzU1lWTDhsendmRi1XRVJSbE5iYno2bDBrV2JNTmtYcnUtUXhfZE5LNjU2WXlqY3E5TzQwLVloMTN2OHQxUFFVT3UxQV9xaW1vRHZOZm9acVZJMlF2THBNMy1PRzQycVc1WUVfNHg0WlFia2w1c3FPa1pGMkhhNUNKWERNZkc?oc=5","date":"2025-01-10","type":"pipeline","source":"Contract Pharma","summary":"Sciwind Biosciences and Verdiva Bio Enter Global Licensing Agreement - Contract Pharma","headline":"Sciwind Biosciences and Verdiva Bio Enter Global Licensing Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQbjd4SWJyWFBZTy1OM0FjN2dKS2ltN0R0V0F1SF9rZDItbE1JblpjX2VEQXhHMWhrcjZLX0Rpa0dSNmI5b2I4T1hTMFdwcHVmY2hfU1AwQXIzMXZoQ04xRVBONnFYM0FyNURNR2hqaV9tWHp5ZXNSZjBjN1psNkdxY1hhVnAtR1pTSHY5ZWo2YzFlQQ?oc=5","date":"2025-01-10","type":"earnings","source":"The Pharma Letter","summary":"Sciwind’s Verdiva Bio deal earnings could top $2.4 billion - The Pharma Letter","headline":"Sciwind’s Verdiva Bio deal earnings could top $2.4 billion","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}